Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease

Summary

This multicenter, phase II, open label study will enroll patients with chronic cold agglutinin disorder. A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11.

Timeline

Start

2012-12

Primary completion

2017-03-27

Completion

2017-03-27

Drugs

Indications